NDATOPICALSOLUTION/DROPSPriority Review
Approved
Dec 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
93
Data completeness
4/8 — Partial
Priority Review
LATISSE (bimatoprost) by AbbVie is analog. First approved in 2008.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LATISSE (bimatoprost) is a topical prostaglandin analog approved in 2008 for enhancing eyelash growth by prolonging the anagen (growth) phase of the hair cycle. Applied directly to the eyelid margin, it is the only FDA-approved prescription treatment for hypotrichosis of the eyelashes. The exact mechanism remains incompletely understood but involves stimulation of hair follicle growth and lengthening.
LOE Approaching
Approaching loss of exclusivity signals declining commercial interest; brand teams are likely consolidating and shifting focus to line extensions or new indications to sustain revenue.
Mechanism of Action
analog. Although the precise mechanism of action is unknown, the growth of eyelashes is believed to occur by increasing the percent of hairs in, and the duration of the anagen or growth phase.
Pharmacologic Class:
Prostaglandin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (93)
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
Started Feb 2026
20 enrolled
GlaucomaOpen-Angle GlaucomaOcular Hypertension+1 more
Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers
Started Feb 2023
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
Started Jun 2022
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
Started Mar 2021
220 enrolled
Open-angle GlaucomaOcular Hypertension
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
Started Jun 2020
37 enrolled
Open-Angle GlaucomaOcular Hypertension
Worked on LATISSE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.